A Clinical Study of HH-1270 in Healthy Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HH-1270 Tablets in Healthy Chinese Participants
This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
SAD consists of 6 prespecified dose levels. Participants are enrolled in cohorts according to the dose-escalation principle and randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of single-dose HH-1270. One dose cohort in the SAD phase will be selected for a food-effect exploration.
MAD consists of 4 prespecified dose levels. Each participant receives once-daily dosing under fasting conditions for 7 consecutive days and is randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of multiple-dose HH-1270.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Xiyu Zhang
- Telefonnummer: 18701650516
- E-mail: zhangxiyu@hhhbio.com
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100191
- Rekruttering
- Peking University Third Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Healthy Chinese adults aged 18 to 55 years (inclusive), both male and female.
- Weight: male ≥50.0 kg, female ≥45.0 kg, and body mass index (BMI) 18.0 to 28.0 kg/m² (inclusive; BMI = weight/height²).
- Results of vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG) at screening are normal or abnormal without clinical significance.
- Participants must agree to take adequate and effective contraceptive measures.
- Participants understand and comply with the study procedures, voluntarily participate, and sign the informed consent form (ICF).
Exclusion Criteria:
- Individuals with severe systemic diseases, infectious diseases, or mental disorders.
- Clinically significant electrocardiogram (ECG) abnormalities.
- History of clinically significant drug allergy or atopic allergic diseases.
- Comorbid conditions that may affect drug absorption, distribution, metabolism, excretion, and interpretation of safety data, or that may reduce compliance, including but not limited to any of the following.
- Positive results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPAb).
- History of drug abuse or alcoholism within 12 months before screening, or evidence of alcohol abuse or excessive drinking confirmed by an alcohol breath test at screening.
- Frequent use of tobacco or nicotine products (e.g., patches, gum, etc.) or any other smoking products within 30 days before screening.
- Blood donation ≥400 mL within 3 months before screening.
- Participation in another interventional clinical trial within 3 months before screening.
- Use of any prescription medication within 4 weeks or 5 half-lives (whichever is longer) before screening.
- Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines, or use of medications that affect drug metabolism, within 2 weeks before screening.
- Known or suspected history of allergy to any component of HH-1270 tablets or their excipients.
- Inability to accept standardized diet management at the study center.
- Participants who are breastfeeding or have a positive pregnancy test before the first dose.
- Participants deemed unsuitable for participation in the study by the investigator.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: HH-1270 group
SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days |
SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days |
|
Placebo komparator: Placebo group
SAD groups will be received HH-1270 placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days |
SAD groups will be received placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Tidsramme: up to 15/21 days in SAD/MAD
|
Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
up to 15/21 days in SAD/MAD
|
|
Clinically significant abnormalities
Tidsramme: up to 14/21 days in SAD/MAD
|
Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v6.0. |
up to 14/21 days in SAD/MAD
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area Under the Plasma Concentration Versus Time Curve (AUC)
Tidsramme: up to 8/14 days in SAD/MAD
|
AUC of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Maximum Plasma Concentration (Cmax)
Tidsramme: up to 8/14 days in SAD/MAD
|
Cmax of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Time to Reach Maximum Plasma Concentration (Tmax)
Tidsramme: up to 8/14 days in SAD/MAD
|
Tmax of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent Terminal Elimination Half-life (T1/2)
Tidsramme: up to 8/14 days in SAD/MAD
|
T1/2 of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent Plasma Clearance (CL/F)
Tidsramme: up to 8/14 days in SAD/MAD
|
CL/F of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
Apparent volume of distribution(Vd/F)
Tidsramme: up to 8/14 days in SAD/MAD
|
Vd/F of HH-1270 in plasma |
up to 8/14 days in SAD/MAD
|
|
To evaluate the TBA level
Tidsramme: up to 15/21 days in SAD/MAD
|
TBA level for each collection point |
up to 15/21 days in SAD/MAD
|
|
To evaluate the CP-1 level
Tidsramme: up to 15/21 days in SAD/MAD
|
CP-1 level for each collection point |
up to 15/21 days in SAD/MAD
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
To evaluate QTc change
Tidsramme: up to 8 days in SAD
|
QTc values in each collection point |
up to 8 days in SAD
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HH1270-101
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .